The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 percent or higher by RP-HPLC | Area percentage of the main peak |
| Identity confirmation | Electrospray ionization mass spectrometry | Observed mass compared with the theoretical value near 751.9 Da |
| Recommended dry storage | -20 °C, desiccated | -80 °C for multi-year archival material |
| Solution handling | Prepare fresh; avoid long storage | Sterile filtration reduces microbial load |
| Common synonyms | TKPRPGP; TP-7 | Sequence code and laboratory designation used interchangeably |
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
=== Discontinued === Acamprosate controlled-release (SNC-102) – various actions [46] ALTO-202 – NMDA receptor antagonist [47] Balovaptan (RG-7314; RO-5028442; RO-5285119) – vasopressin V1 receptor antagonist [48] Brexpiprazole (Lu-AF41156; OPC-34712; Rexulti) – atypical antipsychotic (non-selective monoamine receptor modulator) [49] Carvedilol (Coreg) – α1-, β1-, and β2-adrenergic receptor antagonist and dual alpha/beta blocker [50] Crinecerfont (Crenessity; NBI-74788; SSR-125543) – corticotropin releasing factor receptor 1 (CRF1R) antagonist [51] ENX-105 – dopamine D2 and D3 receptor agonist, dopamine D4 receptor agonist, and serotonin 5-HT1A and 5-HT2A receptor agonist [52] Fluoxetine (Prozac, Sarafem) – selective serotonin reuptake inhibitor [53] Ganaxolone (GNX; CCD-1042; Ztalmy) – GABAA receptor positive allosteric modulator and neurosteroid [54] JZP-150 (PF-04457845; PF-4457845; PF-’845) – fatty acid amide hydrolase (FAAH) inhibitor [55] Nabiximols (tetrahydrocannabinol/cannabidiol; THC/CBD; GW-1000; JZP-378; Nabidiolex®/Tetranabinex®; Sativex) – cannabinoid receptor modulator, other actions [56] Naloxone/tianeptine (TNX-601) – combination of tianeptine (weak and atypical μ-opioid receptor agonist) and naloxone (orally inactive opioid receptor antagonist) Nepicastat (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor [57] NYX-783 – NMDA receptor modulator [58] Orvepitant (GW-823296, GW823296X) – neurokinin NK1 receptor antagonist [59] Pomaglumetad methionil (DB103; LY-2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (pomaglumetad prodrug) [60] PRAX-114 – GABA modulator [61] PRX-3140 (PRX-03140; NTC-942) – serotonin 5-HT4 receptor agonist [62] Verucerfont (GSK-561679; NBI-77860) – corticotropin releasing factor receptor 1 (CRF1R) antagonist [63]
In men, blockade of the AR by bicalutamide in the pituitary gland and hypothalamus prevents the negative feedback of androgens on the hypothalamic–pituitary–gonadal (HPG) axis, resulting in an increase in luteinizing hormone (LH) secretion and levels. Follicle-stimulating hormone (FSH) levels, in contrast, remain essentially unchanged. The increase in LH levels leads to an elevation in androgen and estrogen levels. At a dosage of 150 mg/day, bicalutamide has been found to increase testosterone levels by about 1.5- to 2-fold (59–97% increase) and estradiol levels by about 1.5- to 2.5-fold (65–146% increase). However, there is variability in these increases, and in one clinical trial, the highest testosterone concentration that occurred with 50 mg/day bicalutamide monotherapy was 2,306 ng/dL, which was five times the normal average level of testosterone in men. Levels of DHT are also increased to a lesser extent (by 24–30%), and concentrations of sex hormone-binding globulin (SHBG) and prolactin increase as well (by 8–42% and 40–65%, respectively) secondary to the increase in estradiol levels. The estradiol concentrations produced in men by bicalutamide monotherapy are said to approximate the low-normal estradiol levels of a premenopausal woman, while testosterone levels generally remain in the high end of the normal male range and rarely exceed it.
Calculations in 2007 expected that copernicium may be a semiconductor with a band gap of around 0.2 eV, crystallizing in the hexagonal close-packed crystal structure. However, calculations in 2017 and 2018 suggested that copernicium should be a noble metal at standard conditions with a body-centered cubic crystal structure: it should hence have no band gap, like mercury, although the density of states at the Fermi level is expected to be lower for copernicium than for mercury. 2019 calculations then suggested that in fact copernicium has a large band gap of 6.4 ± 0.2 eV, which should be similar to that of the noble gas radon (predicted as 7.1 eV) and would make it an insulator; bulk copernicium is predicted by these calculations to be bound mostly by dispersion forces, like the noble gases. Like mercury, radon, and flerovium, but not oganesson (eka-radon), copernicium is calculated to have no electron affinity.
Sources: en.wikipedia.org
He was also president of the family's principal philanthropy run by family members, the Rockefeller Brothers Fund, from its inception in 1940 to 1956. In 1929, he joined the family's renowned Rockefeller Foundation; elected to the board in 1931 he subsequently became chairman of this major philanthropic organization for twenty years and was responsible for changing the focus of the institution. The principal philanthropic institution he created was the JDR III Fund in 1963, its major program being the Asian Cultural Program, created in 1967 to encourage East-West cultural exchange. The Fund was wound-up upon his death in 1979, but the Cultural Program continued as the Asian Cultural Council, which has provided grant assistance to more than 4,000 Asians and Americans in the area of the arts. Funding for its programs is derived from a combination of endowment income and contributions from individuals, foundations and corporations in the United States and Asia. In the mid-1950s, John III assumed the leadership of the Exploratory Committee for a Musical Arts Center, a committee of civic leaders who were working to create what would become Lincoln Center. He was the key figure in the fund-raising efforts and in forging a consensus among the civic leaders and others who were essential to its success. The Center itself was built over a period from 1959 to 1969. He was its second president, commencing in 1956, and he became its chairman in 1961. He was chairman until 1970 when he was duly elected honorary chairman.
=== Encoding === Methionine is one of only two amino acids encoded by a single codon (AUG) in the standard genetic code (tryptophan, encoded by UGG, is the other). In reflection to the evolutionary origin of its codon, the other AUN codons encode isoleucine, which is also a hydrophobic amino acid. In the mitochondrial genome of several organisms, including metazoa and yeast, the codon AUA also encodes for methionine. In the standard genetic code AUA codes for isoleucine and the respective tRNA (ileX in Escherichia coli) uses the unusual base lysidine (bacteria) or agmatidine (archaea) to discriminate against AUG. The methionine codon AUG is also the most common start codon. A "Start" codon is message for a ribosome that signals the initiation of protein translation from mRNA when the AUG codon is in a Kozak consensus sequence. As a consequence, methionine is often incorporated into the N-terminal position of proteins in eukaryotes and archaea during translation, although it can be removed by post-translational modification. In bacteria, the derivative N-formylmethionine is used as the initial amino acid.
The allergens in this family include allergens with the following designations: Amb a 1, Amb a 2, Amb a 3, Cha o 1, Cup a 1, Cry j 1, Jun a 1. Two of the major allergens in the pollen of short ragweed (Ambrosia artemisiifolia) are Amb a I and Amb a II. The primary structure of Amb a II has been deduced and has been shown to share ~65% sequence identity with the Amb a I multigene family of allergens. Members of the Amb a I/a II family include Tobacco (Nicotiana tabacum, Common tobacco) pectate lyase, which is similar to the deduced amino acid sequences of two pollen-specific pectate lyase genes identified in Lycopersicon esculentum (Tomato); Cry j I, a major allergenic glycoprotein of Cryptomeria japonica (Japanese cedar)—the most common pollen allergen in Japan; and P56 and P59, which share sequence similarity with pectate lyases of plant pathogenic bacteria. This enzyme belongs to the family of lyases, specifically those carbon-oxygen lyases acting on polysaccharides. The systematic name of this enzyme class is (1->4)-alpha-D-galacturonan lyase. Other names in common use include polygalacturonic transeliminase, pectic acid transeliminase, polygalacturonate lyase, endopectin methyltranseliminase, pectate transeliminase, endogalacturonate transeliminase, pectic acid lyase, pectic lyase, alpha-1,4-D-endopolygalacturonic acid lyase, PGA lyase, PPase-N, endo-alpha-1,4-polygalacturonic acid lyase, polygalacturonic acid lyase, pectin trans-eliminase, and polygalacturonic acid trans-eliminase. This enzyme participates in pentose and glucuronate interconversions.
Sources: en.wikipedia.org
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.
A reported purity value reflects the share of the main peak in one chromatographic run and says nothing about identity. Confirming that the expected sequence is present requires a separate measurement such as mass spectrometry. Purity and identity are distinct questions.
A mass spectrum reports the molecular masses present in a sample and shows whether they match the value expected for selank, near 751.9 Da. It also flags common artifacts such as truncation or adduct formation. It does not establish correct stereochemistry or complete sequence order on its own.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.